Abstract. Finding the minimum number of appropriate biomarkers for specific targets such as a lung cancer has been a challenging issue in bioinformatics. We propose a hierarchical two-phase framework for selecting appropriate biomarkers that extracts candidate biomarkers from the cancer microarray datasets and then selects the minimum number of appropriate biomarkers from the extracted candidate biomarkers datasets with a specific neuro-fuzzy algorithm, which is called a neural network with weighted fuzzy membership function (NEWFM). In this context, as the first phase, the proposed framework is to extract candidate biomarkers by using a Bhattacharyya distance method that measures the similarity of two discrete probability distributions. Finally, the proposed framework is able to reduce the cost of finding biomarkers by not receiving medical supplements and improve the accuracy of the biomarkers in specific cancer target datasets.
Introduction
Recently, as one of diagnostic tools, analysis of diseases by using gene expression microarray datasets has been worldwide used in bioinformatics fields. It needs to use computational methods in that gene expression microarray datasets are very large number of various genes in the gene datasets. It has been a challenging problem to identify the genes that are relevant or not to a clinical diagnosis [1, 5, 15] . As feature selection methods, mutual information [6, 7, 13] , the t-test [14] , threshold number of misclassifications (TNoM) score [8] , and the Bhattacharyya distance [3, 4, 21] have been widely used in finding relevant genes. Feature selection methods have been used for pattern recognition and machine learning [10] .
In these days, feature selection is used for identifying the relevance and influence of the selected gene in gene expression data and it is able to improve the comprehensibility from the results. As specific classifiers in machine learning, k-nearest neighbor (k-NN) [8] , support vector machine (SVM) [8, 11, 12] , and rough set [13] have all been used to verify the efficiency after selecting the genes.
In this context, we propose a hierarchical two-phase framework for selecting effective biomarkers that extracts candidate appropriate biomarkers from the cancer microarray datasets and then selects the minimum number of appropriate biomarkers from the extracted candidate biomarkers with a specific neuro-fuzzy algorithm, which is called a neuro network with weighted fuzzy membership function (NEWFM) [15] [16] [17] .
The proposed framework is to classify tumor biopsies and normal biopsies from a colon cancer data set, and acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL) from a leukemia data set. As the first phase of the proposed process, the Bhattacharyya distance method is used for extracting candidate genes as biomarkers. By using it, we extracted 100 candidate genes in each from the colon dataset that has 2000 genes and the leukemia dataset that has 7129 genes in total. As the second phase of the proposed framework, the minimum number of appropriate genes is selected based on the first phase result.
The minimum of appropriate genes as biomarkers show the highest accuracy by using the NEWFM method. As the minimum, 4 of 100 colon cancer genes and 4 of 100 leukemia genes were selected from the first phase results in 100 colon cancer genes and 100 leukemia genes. The minimum 4 (colon cancer) and 4 (leukemia) genes were used as weighted fuzzy membership functions that preserved the disjunctive fuzzy information and characteristics [15] .
In the remainder of this paper, we describe the proposed framework for selecting the minimum of appropriate genes as biomarkers in Section 2. The accuracy of selecting appropriate genes and the number of genes is evaluated on experimental results that will be shown in Section 3. We also conclude our proposed framework for selecting the appropriate genes and the minimum number of genes in Section 4.
Proposed two-phase process
We propose a hierarchical two-phase framework for selecting the minimum number of appropriate genes with NEWFM. Overall, the proposed framework consists of two phases as following this:
The description of each phase is following this: -First Phase: The proposed framework extracts the candidate genes as biomarkers for the given cancer datasets by using one of similarity measures, called Bhattacharyya distance [3, 4, 21] that is used to calculate the correspondence of discrete probability distributions. For this phase, we used the following equation:
where D B (x, y), σ x is the variance of the distribution and μ x is the mean of the distribution. Thus the more distinguish from each other genes, the bigger value of Bhattacharyya it has. In this experiment, we extract 100 genes from the highest value to 100 th value in each cancer datasets such as leukemia and colon datasets. -Second Phase: From the first phase results, the proposed framework selects more effective and less number of genes as biomarkers. In this phase, we separate the extracted genes into 5 clusters based on the Bhattacharyya distance results and those genes in 5 clusters are input into the NEWFM using the bounded sum of the weighted fuzzy membership functions [15] to select the minimum number of genes with the higher accuracy rate simultaneously. The proposed framework selects again the genes with the higher accuracy rate and the result of NEWFM until reaching the highest accuracy with the minimum number of genes. Overall, the proposed hierarchical two-phase framework means that we first separated the extracted genes into 5 clusters by using the Bhattacharyya distance value and then select the best 4 genes from each 5 cluster based on the result of NEWFM using the bounded sum of the weighted fuzzy membership functions. In hierarchical way, we also select the minimum number of the effective genes from the selected 20 genes based on the result of NEWFM.
Experimental results
We used the two well-known datasets that ALL-AML Leukemia dataset and Colon tumor dataset. Those datasets were from the public Kent Ridge Bio-medical Data Repository [2] .
The leukemia data set contains 72 samples that are divided into two variants of leukemia: 25 samples of acute myeloid leukemia (AML) and 47 samples of acute lymphoblastic leukemia (ALL). Gene expression levels in these 72 samples were measured using high density microarrays reporting the expression levels of 7129 genes. Rewrite, it is copied.
The colon cancer data set consists of 62 samples of colon epithelial cells that are divided into two variants of colon tissue: 40 colon tumor samples and 22 normal colon samples. Gene expression levels in these 62 samples were measured using high density microarrays. 2000 genes were selected based on the confidence in the measured expression levels. Table 1 shows the selected genes in the given cancer datasets with the proposed framework as follows. The accuracies for selecting the minimum number of appropriate genes are shown in Table 2 . The accuracy is the probability of obtaining correct genes in all genes that are from the given datasets. It is defined as:
Accuracy =
All true classified genes All classified genes , where all classified genes are the number of genes that were classified from the given datasets and all true classified genes are true positive (TP) genes and true negative genes (TN) from our experimental results. [18] 94.12% (17) 82.08% (10) Guyon et al. [12] 100% (4) 90.32% (8) Wang et al. [20] 100% (5) 91.9% (3) Proposed framework 100% (4) 95.16% (4) The number in brackets in Table 2 represents the number of selected genes. In this study, AML and ALL in leukemia datasets and tumor biopsies and normal biopsies in colon datasets were classified with the proposed two-phase framework in terms of accuracy and the minimum number of genes. The accuracy of NEWFM was compared with that determined by Cho [18] , Guyon [12] , and Wang [19] . As shown above, our proposed framework selects the minimum genes with highest accuracy of classification.
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Conclusion
In this paper, we proposed a hierarchical two-phase framework for selecting the minimum number of appropriate genes as biomarkers from the given cancer datasets in terms of accuracy. The proposed framework consists of two-phases that the first phase is to extract the candidate genes as biomarkers by using the Bhattacharyya distance measure and the second phase, a hierarchical way for selecting the minimum number of appropriate genes with NEWFM from the extracted genes as biomarkers. As shown in Section 3, the proposed framework showed higher accuracy compared to other methods [12, 18, 19] with the minimum genes.
Finally, as our future work, to robust our proposed framework of selecting the effective and the minimum number of biomarkers, we will experiment with another bigger size of various cancer type datasets.
